Diabetes

Treating blood sugar disease with with a natural sweetener: Sugar-based therapy for diabetes (TIIDM): Phyllodulcin, a natural sweetener 400-800 times sweeter than sugar, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 28/March/2018, 10.38 am

Treating blood sugar disease with with a natural sweetener: Sugar-based therapy for diabetes (TIIDM): Phyllodulcin, a natural sweetener 400-800 times sweeter than sugar, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 28/March/2018, 10.38 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Hydrogen gas-based therapy for body weight control, energy homeostasis and TIIDM: Hydrogen gas decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 27/March/2017, 10.48 pm

Hydrogen gas-based therapy for body weight control, energy homeostasis and TIIDM: Hydrogen gas decreases CADM1 and its downstream target genes that inhibit glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 27/March/2017, 10.48 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by neuronal cell adhesion molecule1.”…

read more

Sugar-based therapy for diabetes (TIIDM): Lactulose (brand name: Cholac, Generlac, Consulose, Duphalac), a drug used in the treatment of constipation and hepatic encephalopathy, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 27/March/2018, 5.50 am

Sugar-based therapy for diabetes (TIIDM): Lactulose (brand name: Cholac, Generlac, Consulose, Duphalac), a drug used in the treatment of constipation and hepatic encephalopathy, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 27/March/2018, 5.50 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Sugar-based therapy for diabetes (TIIDM): D-Fagomine, an iminosugar isolated from mulberry leaves, among others, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/March/2018, 12.55 am

Sugar-based therapy for diabetes (TIIDM): D-Fagomine, an iminosugar isolated from mulberry leaves, among others, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 24/March/2018, 12.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

Molecular therapy for diabetes (TIDM): Ankaflavin, a secondary metabolite produced by yeast monascus purpureus, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 21/March/2018, 2.07 pm

Molecular therapy for diabetes (TIDM): Ankaflavin, a secondary metabolite produced by yeast monascus purpureus, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 21/March/2018, 2.07 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more

A candy way to say no to Diabetes: Sugar-based therapy for diabetes (TIDM): D-Mannose, a C-2 epimer of glucose, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 18/March/2018,11.15 pm

A candy way to say no to Diabetes: Sugar-based therapy for diabetes (TIDM): D-Mannose, a C-2 epimer of glucose, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 18/March/2018,11.15 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more